FGD2 | FYVE, RhoGEF and PH domain containing 2 | Cytoskeleton related proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
FLT3 | Fms-related tyrosine kinase 3 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FRZB | Frizzled-related protein | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
FZD8 | Frizzled class receptor 8 | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GDF3 | Growth differentiation factor 3 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
GDPD2 | Glycerophosphodiester phosphodiesterase domain containing 2 | Cytoskeleton related proteins Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
GIMAP1 | GTPase, IMAP family member 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
GJD3 | Gap junction protein, delta 3, 31.9kDa | Predicted membrane proteins
| | | | | Tissue enhanced |
GP9 | Glycoprotein IX (platelet) | CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
GRAP | GRB2-related adaptor protein | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
GRAPL | GRB2-related adaptor protein-like | Predicted intracellular proteins
| | | | | Tissue enhanced |
GZMM | Granzyme M (lymphocyte met-ase 1) | Enzymes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
HCAR3 | Hydroxycarboxylic acid receptor 3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
HIST2H3PS2 | Histone cluster 2, H3, pseudogene 2 | Predicted intracellular proteins
| | | | | Tissue enhanced |
HMHA1 | Histocompatibility (minor) HA-1 | Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
HYAL1 | Hyaluronoglucosaminidase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IGSF21 | Immunoglobin superfamily, member 21 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IGSF6 | Immunoglobulin superfamily, member 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAX | Integrin, alpha X (complement component 3 receptor 4 subunit) | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
KANK3 | KN motif and ankyrin repeat domains 3 | Predicted intracellular proteins
| | | | | Tissue enhanced |
KAZALD1 | Kazal-type serine peptidase inhibitor domain 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
KAZN | Kazrin, periplakin interacting protein | Predicted intracellular proteins
| | | | | Tissue enhanced |
KCNB2 | Potassium voltage-gated channel, Shab-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KIR2DL1 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KIR2DL3 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KIR2DL4 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
KIR3DL1 | Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KIR3DL2 | Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KLRC2 | Killer cell lectin-like receptor subfamily C, member 2 | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
KLRC3 | Killer cell lectin-like receptor subfamily C, member 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRC4 | Killer cell lectin-like receptor subfamily C, member 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRD1 | Killer cell lectin-like receptor subfamily D, member 1 | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
KLRF1 | Killer cell lectin-like receptor subfamily F, member 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRA1 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRA2 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 | CD markers Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRA4 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LILRB1 | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRB5 | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5 | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
LIMD2 | LIM domain containing 2 | Predicted intracellular proteins
| | | | | Tissue enhanced |
LINGO3 | Leucine rich repeat and Ig domain containing 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
LRRC25 | Leucine rich repeat containing 25 | Predicted membrane proteins
| | | | | Tissue enhanced |
MADCAM1 | Mucosal vascular addressin cell adhesion molecule 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
MATK | Megakaryocyte-associated tyrosine kinase | Cancer-related genes Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
MDS2 | Myelodysplastic syndrome 2 translocation associated | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
MEFV | Mediterranean fever | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
MMP25 | Matrix metallopeptidase 25 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |